NCT05955339 Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
| NCT ID | NCT05955339 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dartmouth-Hitchcock Medical Center |
| Condition | Diabetes Mellitus |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,022 participants |
| Start Date | 2024-01-24 |
| Primary Completion | 2027-04-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,022 participants in total. It began in 2024-01-24 with a primary completion date of 2027-04-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CHRONICLE is a randomized trial assessing the comparative effectiveness of providing written visit information via the patient portal (NOTES) versus NOTES plus visit audio recording (AUDIO) to older adult patients with chronic diseases on quality of life and other outcomes. During the trial, the team will also invite caregivers identified by patients to join the project.
Eligibility Criteria
PATIENTS: Inclusion Criteria: * ≥ 65 years; * With multimorbidity (diabetes or hypertension plus one of the following: arthritis (osteoarthritis and rheumatoid arthritis), asthma, atrial fibrillation, Alzheimer's disease and related dementia (not severe), cancer, chronic obstructive pulmonary disease, depression, heart disease, heart failure, hyperlipidemia, osteoporosis, kidney disease and stroke. Patients with diabetes plus hypertension are eligible. * Have had two or more clinic visits in the previous 12 months; * Plan on receiving ongoing care at the clinic with the enrolled clinician for the subsequent 6 months; * Do not have vision or hearing problems that cannot be corrected; and * Have not recorded a clinic visit for personal use in the past 6 months Exclusion Criteria: * With no capacity to consent to the project; * With schizophrenia and other psychotic disorders, current substance-use disorders, uncorrected hearing or visual impairment with no adjustments to support accessing the interventions or surveys; * Living in skilled nursing homes or hospice, because they engage less in self-management; * With cognitive impairment as identified by a score of ≤4 on the six-item screener (SIS) * Lacking internet access; * Who do not speak English or Spanish; * Who (i) do not have access to a personal email, (ii) do not have an email address shared with a family member or patient-identified caregiver, and/or (iii) are not interested in creating a personal email as this would prevent them from engaging with the intervention(s); and * Who do not wish to create a patient portal account, if they do not already have one as this would prevent them from engaging with the intervention(s). CAREGIVERS: Inclusion criteria: * Agree to their identified role as a caregiver; * Speak English or Spanish; * Have capacity to consent to research participation; and * ≥ 18 years. Exclusion criteria: * No capacity to consent to the project; * Living in skilled nursing homes or hospice; * Lacking internet access; or * Do not speak English or Spanish
Contact & Investigator
Paul J Barr, PhD
PRINCIPAL INVESTIGATOR
Dartmouth College
Frequently Asked Questions
Who can join the NCT05955339 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05955339 currently recruiting?
Yes, NCT05955339 is actively recruiting participants. Contact the research team at paul.j.barr@dartmouth.edu for enrollment information.
Where is the NCT05955339 trial being conducted?
This trial is being conducted at Manchester, United States, Nashville, United States, Galveston, United States.
Who is sponsoring the NCT05955339 clinical trial?
NCT05955339 is sponsored by Dartmouth-Hitchcock Medical Center. The principal investigator is Paul J Barr, PhD at Dartmouth College. The trial plans to enroll 1,022 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.